GENE ONLINE|News &
Opinion
Blog

Eli Lilly
Eli Lilly’s Orforglipron Shows Phase 3 Success: First Oral GLP-1 Drug for Type 2 Diabetes and Weight Loss
2025-04-21
Novo Nordisk Introduces Lower-Cost Wegovy via Direct-to-Patient Sales Platform
2025-03-06
Novo Nordisk Takes on Eli Lilly in Weight Loss Drug Battle with Wegovy Price Cut
2025-03-06
Eli Lilly Commits $27 Billion to Expand U.S. Drug Manufacturing Amid Presidential Push
2025-02-27
Lilly Slashes Zepbound Vial Prices by Up to 50% to Expand Access for Uninsured Patients
2025-02-26
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
Lilly’s Omvoh’s Two-Year Journey Confirms Lasting Impact on Crohn’s Disease Treatment
2025-02-08
Eli Lilly Steals the Spotlight at JPM 2025 with $2.5 Billion Power Move Acquisition
2025-01-16
Eli Lilly’s Zepbound Becomes First and Only FDA Approved Weight Loss Drug to Treat Obstructive Sleep Apnea
2024-12-23
Eli Lilly’s Alzheimer’s Treatment Kisunla Secures Fourth Major Market Approval with NMPA Authorization in China
2024-12-18
China’s Laekna Joins Forces with Weight-Loss Giant Lilly on Muscle-Preserving Obesity Drug in Expanding $150B Market
2024-11-21
Novartis Invests $745M to Compete with BMS and Lilly in the Radiopharma Race
2024-11-19
FDA to Reassess Shortage Status of Key Obesity Drugs; Compounding Stocks Out of the Red—for Now
2024-10-16
Lilly Invests $4.5B in Indiana Facility for In-House Clinical Manufacturing
2024-10-03
Can New GLP-1 Contenders Disrupt the Weight-Loss Giants, Lilly and Novo, in the Battle for Market Dominance?
2024-10-03
1 2 3 6
LATEST
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Roche Announces Massive 50 Billion Dollar Investment in the United States
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24
Arkansas Medicaid Work Requirements Led to Coverage Loss for a Significant Number of Recipients
2025-04-24
Boehringer agrees new partnership to advance first-in-class precision cancer therapies
2025-04-24
Bristol Myers Squibb Schizophrenia Drug Fails Pivotal Test as an Add-On to Antipsychotics
2025-04-24
EVENT
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
Scroll to Top